According to Zhitong Finance App News, Haichuang Pharmaceutical (688302.SH) released its report for the third quarter of 2026. The company achieved operating income of 857.277 million yuan in the first three quarters, an increase of 267.11% over the previous year; a net loss attributable to shareholders of listed companies of 101 million yuan; a net loss of 114 million yuan attributable to shareholders of listed companies after deducting non-recurring profit and loss; and basic earnings per share - 1.02 yuan.

^{In the first three quarters, the year-on-year increase in the company's revenue was mainly due to the company's first Class 1 drug Hainaan® being included in the national medical insurance drug catalogue in December 2025 (officially implemented on January 1, 2026), and drug sales revenue increased this year.}

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.